Ghent University Academic Bibliography

Your filters: cql: author="Castellano, Daniel" or (type any "bookEditor issueEditor" and editor="Castellano, Daniel")

Add to list
A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)

Marit Ahrens, Bernard Escudier, Ekaterini Boleti, Marc-Oliver Grimm, Marine Gross Goupir, Pilippe Barthelemy, Gwenaelle Gravis, Jens Bedekes, Philipp Ivanyi, Andrej Panic, et al.

(2020) ONCOLOGY RESEARCH AND TREATMENT. 43(15 (Suppl. 1)). p.226-226
Add to list
- Journal Article
- A1
- open access
Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

Ronald de Wit, Johann de Bono, Cora N. Sternberg, Karim Fizazi, Bertrand Tombal, Christian Wülfing, Gero Kramer, Jean-Christophe Eymard, Aristotelis Bamias, Joan Carles, et al.

(2019) NEW ENGLAND JOURNAL OF MEDICINE. 381(26). p.2506-2518
Add to list
- Journal Article
- A1
- open access
Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma

Robert J. Motzer, Nizar M. Tannir, David F. McDermott, Osvaldo Arén Frontera, Bohuslav Melichar, Toni K. Choueiri, Elizabeth R. Plimack, Philippe Barthélémy, Camillo Porta, Saby George, et al.

(2018) NEW ENGLAND JOURNAL OF MEDICINE. 378(14). p.1277-1290
Add to list
- Journal Article
- A1
- open access
Management of patients with advanced prostate cancer : the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Silke Gillessen, Gerhardt Attard, Tomasz M Beer, Himisha Beltran, Alberto Bossi, Rob Bristow, Brett Carver, Daniel Castellano, Byung Ha Chung, Noel Clarke, et al.

(2018) EUROPEAN UROLOGY. 73(2). p.178-211
Add to list
- Journal Article
- A1
- open access
Nivolumab versus everolimus in advanced renal-cell carcinoma

Robert J. Motzer, Bernard Escudier, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, et al.

(2015) NEW ENGLAND JOURNAL OF MEDICINE. 373(19). p.1803-1813
Add to list
An international expanded-access programme of everolimus : addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Viktor Grünwald, Pierre I. Karakiewicz, Sevil E. Bavbek, Kurt Miller, Jean-Pascal Machiels, Se-Hoon Lee, James Larkin, Petri Bono, Sun Young Rha, Daniel Castellano, et al.

(2012) EUROPEAN JOURNAL OF CANCER. 48(3). p.324-332

Academic Bibliography

A randomized phase II study of Nivolumab plus Ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (Suniforecast)

Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer

Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma

Management of patients with advanced prostate cancer : the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017

Nivolumab versus everolimus in advanced renal-cell carcinoma

An international expanded-access programme of everolimus : addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Contents

Support

Contact